Cover Image
市場調查報告書

首發注射劑

Branded Injectables to 2020

出版商 Greystone Research Associates 商品編碼 300894
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
首發注射劑 Branded Injectables to 2020
出版日期: 2014年05月02日 內容資訊: 英文
簡介

由於塗料劑、設備設計的進步,不過幾年前不可能的預填充式生技藥品成為可能。預填充式藥管,降低筆型注射器、自行注射器的成本,慢性疾病可進入更大的市場區隔。

本報告提供首發(品牌)注射劑市場相關資料相關研究、主要10個治療領域分析、設計與技術相關的問題,及今後的預測等等,為您概述為以下內容。

調查焦點

  • 治療的主要十大市場的治療需求的促進要素分析、品牌注射劑的評估
  • 設計要素、材料選擇的問題、技術及市場開發問題分析
  • 品牌注射劑影響市場的重大管理護理,技術及法規要素的評估
  • 市場資料與預測的提供

目錄

  • 摘要整理
  • 抗凝血劑
  • 抗病毒劑
  • 自體免疫疾病
  • 多發性硬化症
  • 糖尿病
  • 造血劑
  • 荷爾蒙補充
  • 偏頭痛
  • 骨質疏鬆症
  • 生殖健康
目錄
Product Code: BRJ613F

Advances in coatings and device designs have led to prefilled biologicals in patient-friendly drug-device combination products that were not possible just a few years ago. Prefilled drug cartridges have reduced the cost of injectable pens and autoinjectors, making them accessible to a larger segment of the chronically ill. Injectors with advanced features such as variable dosing, dose counters and audible cues are making self-administration safer for patients prescribed immune modulators with black box warnings. To streamline the drug-device development process, drug developers are increasingly aligning themselves with device suppliers, increasing the level of concurrent engineering, identifying design challenges earlier and minimizing possible delays that could result. This trend represents risks for injectable drug firms competing for device solutions for their sophisticated formulations. It is also an opportunity for smaller device suppliers who are able to demonstrate the financial and technological resources to address the needs of injectable drug developers.

Convergence and Evolution in Key Markets

The administration of therapeutic drugs via injection is an indispensable delivery method for numerous drugs critical to patient health and well-being. Now this segment is evolving in response to changing patient populations, new classes of powerful therapeutic drugs and healthcare administration initiatives. A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patientfriendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.

Highlights

  • Analyzes therapeutic demand drivers and evaluates branded injectables in ten major therapeutic markets
  • Analyzes design factors, material selection issues, technologies and market development issues
  • Assess significant managed care, technology, and regulatory factors affecting branded injectable drug markets.
  • Provides market data and forecasts to 2020

SAMPLE

Charts, Graphs and Tables Designed to Provide Insight and Clarify

Table of Contents

  • Executive Summary
  • Anticoagulants
  • Antivirals
  • Autoimmune Diseases
  • Multiple Sclerosis
  • Diabetes
  • Hematopoietics
  • Hormone Replacement
  • Migraine
  • Osteoporosis
  • Reproductive Health
Back to Top